Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone in Chronic LHON
NCT01495715Phase 3Withdrawn
- Sponsor
- Santhera Pharmaceuticals
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Leber hereditary optic neuropathy (LHON) comparing Idebenone with Placebo (2 arms). Primary endpoint: Time to improvement of visual acuity. Status: withdrawn.
02
Drugs
idebenone
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT01495715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01495715.